Spec­trum im­plodes af­ter a harsh pub­lic slap­down and now a CRL from Richard Paz­dur

The FDA has gone out of its way sev­er­al times to flat­ten any ex­pec­ta­tions for Spec­trum’s lung can­cer drug pozi­o­tinib, in­clud­ing slam­ming the reg­u­la­to­ry door …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER